FDC Limited
NSE: FDC BSE: FDC
NSE
430.60
0.15 (0.03%)
Prev Close
430.45
Open Price
430
Volume
67,489
Today Low / High
423.1 / 432.95
52 WK Low / High
366.25 / 658.85
Range
409 - 452
BSE
431.00
0.75 (0.17%)
Prev Close
430.25
Open Price
412.75
Volume
1,980
Today Low / High
423.1 / 431.4
52 WK Low / High
358.95 / 659
Range
409 - 453
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 430.6 (target range: 409 - 452), reflecting a change of 0.15 (0.03484725%). On the BSE, it is listed at 431 (target range: 409 - 453), showing a change of 0.75 (0.17432%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
430.00
0.14%
17 Apr
426.00
1.04%
16 Apr
425.00
1.36%
15 Apr
425.50
-0.12%
11 Apr
410.45
2.69%
09 Apr
406.35
0.11%
08 Apr
398.10
3.25%
07 Apr
389.95
1.72%
04 Apr
411.00
-3.10%
03 Apr
405.20
1.46%
02 Apr
401.85
-0.27%
01 Apr
394.10
1.97%
28 Mar
399.00
-1.27%
27 Mar
388.90
1.54%
26 Mar
405.50
-4.39%
25 Mar
415.00
-1.41%
24 Mar
415.05
0.08%
FDC Limited Graph
FDC Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for FDC Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 430.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 431.00 | 435.31 | 391.78 - 478.84 |
| 439.62 | 351.70 - 527.54 | ||
| 443.93 | 310.75 - 577.11 | ||
| Bearish Scenario | 431.00 | 426.69 | 384.02 - 469.36 |
| 422.38 | 337.90 - 506.86 | ||
| 418.07 | 292.65 - 543.49 |
Overview of FDC Limited
ISIN
INE258B01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
128,475
Market Cap
70,106,024,754
Last Dividend
10
Official Website
IPO Date
2002-07-01
DCF Diff
-227.84
DCF
659
Financial Ratios Every Investor Needs
Stock Dividend of FDC
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-11-22 | November 22, 24 | 5 | 5 | 2024-11-22 | 2024-12-06 | |
| 2020-03-19 | March 19, 20 | 0.8 | 0.8 | 2020-03-21 | 2020-03-31 | 2020-03-09 |
| 2017-08-08 | August 08, 17 | 2.25 | 2.25 | 2017-08-09 | 2017-09-18 | 2017-05-26 |
| 2016-03-17 | March 17, 16 | 2.25 | 2.25 | 2016-03-19 | 2016-03-23 | 2016-03-09 |
| 2015-09-23 | September 23, 15 | 2.25 | 2.25 | 2015-09-25 | 2015-10-30 | 2015-05-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,935.20 Cr | 1,284.32 Cr | 650.88 Cr | 0.3363 | 18.48 Cr | 22.50 Cr | 303.37 Cr | 305.22 Cr | 18.59 | 440.17 Cr | 0.1577 |
| 2023-03-31 | 1,783.75 Cr | 655.79 Cr | 1,127.96 Cr | 0.6324 | 17.10 Cr | 17.20 Cr | 212.04 Cr | 194.04 Cr | 11.67 | 300.83 Cr | 0.1088 |
| 2022-03-31 | 1,525.75 Cr | 547.45 Cr | 978.29 Cr | 0.6412 | 15.85 Cr | 9.81 Cr | 216.38 Cr | 216.40 Cr | 12.82 | 329.78 Cr | 0.1418 |
| 2021-03-31 | 1,326.83 Cr | 426.96 Cr | 899.87 Cr | 0.6782 | 13.26 Cr | 9.31 Cr | 296.24 Cr | 301.35 Cr | 17.73 | 428.95 Cr | 0.2271 |
| 2020-03-31 | 1,337.42 Cr | 436.78 Cr | 900.64 Cr | 0.6734 | 7.67 Cr | 12.71 Cr | 267.27 Cr | 239.88 Cr | 13.94 | 361.84 Cr | 0.1794 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 25.42 Cr | 2,468.09 Cr | 370.92 Cr | 2,097.1690 Cr | 20.52 Cr | -4.90 Cr | 388.89 Cr | 949.47 Cr | 5.11 Cr | 0.00 Cr | 392.75 Cr | 310.6230 Cr |
| 2023-03-31 | 23.89 Cr | 2,342.94 Cr | 361.54 Cr | 1,982.0479 Cr | 28.32 Cr | 4.43 Cr | 328.54 Cr | 892.93 Cr | 113.37 Cr | 18.65 Cr | 348.49 Cr | 311.5576 Cr |
| 2022-03-31 | 37.73 Cr | 2,270.20 Cr | 313.84 Cr | 1,956.7904 Cr | 32.20 Cr | -5.52 Cr | 304.70 Cr | 838.64 Cr | 128.29 Cr | 0.98 Cr | 384.73 Cr | 272.1553 Cr |
| 2021-03-31 | 30.43 Cr | 1,956.23 Cr | 222.27 Cr | 1,734.1349 Cr | 14.54 Cr | -15.90 Cr | 214.92 Cr | 719.15 Cr | 110.30 Cr | 1.11 Cr | 265.36 Cr | 203.9991 Cr |
| 2020-03-31 | 29.88 Cr | 1,812.93 Cr | 265.50 Cr | 1,547.4296 Cr | 15.08 Cr | -14.80 Cr | 209.96 Cr | 695.29 Cr | -5.45 Cr | 0.67 Cr | 162.31 Cr | 246.3387 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 220.7674 Cr | -17.0832 Cr | -202.1572 Cr | 127.3742 Cr | 1.5337 Cr | 25.4201 Cr | -93.3932 Cr | 305.2233 Cr | -0.0759 Cr | -0.1468 Cr | -57.9576 Cr |
| 2023-03-31 | 154.9131 Cr | 11.1346 Cr | -179.9501 Cr | 41.8206 Cr | -13.8389 Cr | 23.8864 Cr | -113.0925 Cr | 257.8033 Cr | -9.6243 Cr | -0.1777 Cr | -23.8402 Cr |
| 2022-03-31 | 161.6522 Cr | -144.5669 Cr | -9.8366 Cr | 29.1080 Cr | 7.2938 Cr | 37.7253 Cr | -132.5442 Cr | 289.3901 Cr | -0.1357 Cr | 0.0000 Cr | -89.7751 Cr |
| 2021-03-31 | 207.0815 Cr | -77.1536 Cr | -129.3490 Cr | 144.5421 Cr | 0.5546 Cr | 30.4315 Cr | -62.5394 Cr | 389.8541 Cr | -2.9220 Cr | 0.0000 Cr | -4.9601 Cr |
| 2020-03-31 | 250.3806 Cr | -98.3523 Cr | -141.9971 Cr | 219.1479 Cr | 9.9606 Cr | 29.8769 Cr | -31.2327 Cr | 319.9542 Cr | -6.0977 Cr | -13.7045 Cr | -36.1745 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 464.11 Cr | 160.92 Cr | 303.19 Cr | 0.6533 | 33.30 Cr | 37.04 Cr | 2.28 | 65.48 Cr | 0.0798 |
| 2024-09-30 | 513.85 Cr | 321.77 Cr | 192.07 Cr | 0.3738 | 56.37 Cr | 72.04 Cr | 4.42 | 104.86 Cr | 0.1402 |
| 2024-06-30 | 638.27 Cr | 359.22 Cr | 279.05 Cr | 0.4372 | 135.59 Cr | 119.04 Cr | 7.31 | 175.05 Cr | 0.1865 |
| 2024-03-31 | 462.03 Cr | 267.05 Cr | 194.98 Cr | 0.4220 | 45.89 Cr | 46.28 Cr | 2.84 | 76.60 Cr | 0.1002 |
| 2023-12-31 | 458.17 Cr | 150.76 Cr | 307.41 Cr | 0.6709 | 98.52 Cr | 79.23 Cr | 4.87 | 108.49 Cr | 0.1729 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 44.42 Cr | 558.75 Cr | 603.17 Cr | 174.80 Cr | 322.85 Cr | 1,147.02 Cr | 943.71 Cr | 2,688.08 Cr | 396.35 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 476.32 Cr | 0.00 Cr | 0.00 Cr | 476.32 Cr | 0.00 Cr | 0.00 Cr | -2,097.17 Cr |
| 2024-03-31 | 26.29 Cr | 450.03 Cr | 476.32 Cr | 117.38 Cr | 388.89 Cr | 1,062.50 Cr | 937.56 Cr | 2,468.09 Cr | 370.92 Cr |
| 2023-12-31 | -382.65 Cr | 765.31 Cr | 382.65 Cr | 0.00 Cr | 0.00 Cr | 382.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 22.48 Cr | 362.49 Cr | 384.97 Cr | 158.57 Cr | 340.97 Cr | 975.57 Cr | 912.35 Cr | 2,341.68 Cr | 369.83 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 119.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 46.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 79.23 Cr | 19.95 Cr | 0.00 Cr | 0.00 Cr | 19.95 Cr | 43.34 Cr | 23.39 Cr | 0.00 Cr | 19.95 Cr |
| 2023-09-30 | 69.82 Cr | 125.24 Cr | 70.19 Cr | -197.02 Cr | -2.31 Cr | 22.48 Cr | 24.79 Cr | -56.66 Cr | 68.57 Cr |
| 2023-06-30 | 109.89 Cr | 19.27 Cr | 0.00 Cr | 0.00 Cr | 19.27 Cr | 43.61 Cr | 24.34 Cr | 0.00 Cr | 19.27 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2004-04-29 | April 29, 04 | 2:1 |
| 2002-05-14 | May 14, 02 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
BR Head, MD & Director
Mr. Mohan Anand Chandavarkar
Gender: male
Year Born:
Joint MD & Executive Director
Dr. Nandan Mohan Chandavarkar
Gender: Not Specified
Year Born:
Chief Financial Officer
Mr. Vijay Dharmadatt Bhatt
Gender: male
Year Born:
Whole Time Director
Mr. Ashok Anand Chandavarkar
Gender: male
Year Born:
Chief Executive Officer of International Business & Executive Director
Mr. Ameya Ashok Chandavarkar
Gender: male
Year Born: 1978
President of Technical & Operations
Mr. Lalit Aggarwal
Gender: male
Year Born:
Compliance Officer & Company Secretary
Ms. Varsharani Rajaram Katre C.S.
Gender: female
Year Born:
Associate Vice President of Technical & Operations
Mr. Shashank Vyapari
Gender: male
Year Born:
Associate Vice President of Engineering Services & Projects
Mr. Anant Kharche
Gender: male
Year Born:
Vice President of Corporate Finance
Mr. Sanjay B. Jain
Gender: male
Year Born:
FAQs about FDC Limited
Who is the CEO of the company?
The CEO is Mr. Ameya Ashok Chandavarkar.
What is the current market price of the stock?
The current price is ₹430.60.
What is the 52-week price range?
The range is ₹366.25-658.85.
What is the market capitalization of the company?
The market capitalization is ₹7,010.60 crores.
What is the dividend yield?
The dividend yield is 1.16%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 25.49.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of FDC Limited (ISIN: INE258B01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹7,010.60 crores and an average daily volume of 128,475 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹10.